These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6374043)

  • 21. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
    Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I clinical trial of CO17-1A monoclonal antibody.
    Lobuglio AF; Saleh M; Peterson L; Wheeler R; Carrano R; Huster W; Khazaeli MB
    Hybridoma; 1986 Jul; 5 Suppl 1():S117-23. PubMed ID: 3488950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival.
    Moulton HM; Yoshihara PH; Mason DH; Iversen PL; Triozzi PL
    Clin Cancer Res; 2002 Jul; 8(7):2044-51. PubMed ID: 12114402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer.
    Saleh MN; Khazaeli MB; Wheeler RH; Bucy RP; Liu T; Everson MP; Munn DH; Schlom J; LoBuglio AF
    Cancer Res; 1995 Oct; 55(19):4339-46. PubMed ID: 7671245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results.
    Sindelar WF; Maher MM; Herlyn D; Sears HF; Steplewski Z; Koprowski H
    Hybridoma; 1986 Jul; 5 Suppl 1():S125-32. PubMed ID: 3744377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes.
    Fagerberg J; Hjelm AL; Ragnhammar P; Frödin JE; Wigzell H; Mellstedt H
    Cancer Res; 1995 May; 55(9):1824-7. PubMed ID: 7728746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
    Mulligan T; Carrasquillo JA; Chung Y; Milenic DE; Schlom J; Feuerstein I; Paik C; Perentesis P; Reynolds J; Curt G
    Clin Cancer Res; 1995 Dec; 1(12):1447-54. PubMed ID: 9815943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
    Alvarez RD; Huh WK; Khazaeli MB; Meredith RF; Partridge EE; Kilgore LC; Grizzle WE; Shen S; Austin JM; Barnes MN; Carey D; Schlom J; LoBuglio AF
    Clin Cancer Res; 2002 Sep; 8(9):2806-11. PubMed ID: 12231520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial trial use of murine monoclonal antibodies as immunotherapeutic agents for gastrointestinal adenocarcinoma.
    Sears HF; Herlyn D; Steplewski Z; Koprowski H
    Hybridoma; 1986 Jul; 5 Suppl 1():S109-15. PubMed ID: 3488949
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor.
    Shetye J; Ragnhammar P; Liljefors M; Christensson B; Frödin JE; Biberfeld P; Mellstedt H
    Clin Cancer Res; 1998 Aug; 4(8):1921-9. PubMed ID: 9717820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies.
    Alpaugh RK; Schultz J; McAleer C; Giantonio BJ; Persson R; Burnite M; Nielsen SE; Vitek L; Persson B; Weiner LM
    Clin Cancer Res; 1998 Aug; 4(8):1903-14. PubMed ID: 9717818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased production of anti-mouse antibody after administration of human/mouse chimeric monoclonal antibody-neocarzinostatin conjugate to human.
    Yata Y; Otsuji E; Okamoto K; Tsuruta H; Kobayashi S; Toma A; Yamagishi H
    Hepatogastroenterology; 2003; 50(49):80-4. PubMed ID: 12629996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.
    Chapman PB; Wu D; Ragupathi G; Lu S; Williams L; Hwu WJ; Johnson D; Livingston PO
    Clin Cancer Res; 2004 Jul; 10(14):4717-23. PubMed ID: 15269144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.
    McCaffery M; Yao TJ; Williams L; Livingston PO; Houghton AN; Chapman PB
    Clin Cancer Res; 1996 Apr; 2(4):679-86. PubMed ID: 9816218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
    Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
    Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model.
    Velders MP; van Rhijn CM; Briaire IH; Fleuren GJ; Warnaar SO; Litvinov SV
    Cancer Res; 1995 Oct; 55(19):4398-403. PubMed ID: 7671252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serotherapy of cancer.
    Harris DT; Mastrangelo MJ
    Semin Oncol; 1989 Jun; 16(3):180-98. PubMed ID: 2658082
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.